The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention

PURPOSE: Studies of SF1126, an RGDS targeted, water-soluble prodrug of LY294002, are currently nearing completion in two adult Phase I trials. Herein, we performed a preclinical evaluation of SF1126 as a PI-3K inhibitor for Phase I trials in the treatment of recurrent neuroblastoma (NB). METHODS: Th...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Peirce, Susan K., Findley, Harry W., Prince, Chengyu, Dasgupta, Anindya, Cooper, Todd, Durden, Donald L.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer-Verlag 2010
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3143317/
https://ncbi.nlm.nih.gov/pubmed/20972874
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-010-1486-7
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia